论文部分内容阅读
[目的]探讨SOCS1沉默的树突状细胞过继免疫治疗胃癌患者过程中,对患者体内IFN-γ、TNF-α、Anti-MUC1的影响。[方法]入组15例接受SOCS1沉默的树突状细胞(DC)治疗的胃癌患者,细胞治疗前检测患者体内IFN-γ、TNF-α、Anti-MUC1滴度,治疗后30天复查患者体内IFN-γ、TNF-α、Anti-MUC1滴度。同时设立对照组。[结果 ]SOCS1沉默的树突状细胞过继免疫治疗胃癌患者治疗前后CD4+细胞内IFN-γ、TNF-α,CD8+细胞内TNF-α,患者血清Anti-MUC1滴度,配对t检验结果显示差异均有统计学意义。治疗前后CD8+细胞内IFN-γ,非参数检验结果显示差异有统计学意义。[结论]用SOCS1沉默的树突状细胞过继免疫回输治疗可以提高患者体内的抗肿瘤免疫效应。
[Objective] To investigate the effect of SOCS1-silenced dendritic cells on the level of IFN-γ, TNF-α and Anti-MUC1 during adoptive immunotherapy of patients with gastric cancer. [Methods] Totally 15 gastric cancer patients receiving SOCS1-silenced dendritic cells (DCs) were enrolled. Before treatment, the titers of IFN-γ, TNF-α and Anti-MUC1 in the patients were examined. IFN-γ, TNF-α, Anti-MUC1 titers. At the same time set up a control group. [Results] The levels of IFN-γ, TNF-α, TNF-α in CD4 + cells and serum Anti-MUC1 titers in patients with SOCS1-silenced dendritic cells treated with adoptive immunotherapy before treatment were significantly lower than those in control There is statistical significance. Before and after treatment IFN-γ in CD8 + cells, non-parametric test showed that the difference was statistically significant. [Conclusion] The adoptive immunotherapy with dendritic cells silenced by SOCS1 can improve the anti-tumor immune effect in patients.